CLAIMS

1. A composition comprising a fusion protein comprising at least two cytokines, wherein the cytokines are CCL20 and IL-1β, and

wherein at least one cytokine comprises a mutation that strongly reduces binding activity to its receptor, and at least one cytokine is a wild type cytokine which provides cell-specific targeting that restores activity of the mutant cytokine on the targeted cells.

2. The composition according to claim 1, further comprising a GGS linker.

3. The composition of claim 1 or 2, wherein the IL-1β comprises the mutation.

4. The composition of claim 3, wherein the mutation is at a position selected from 120, 131, 146, 148, and 209.

5. The composition of claim 4, wherein the mutation is selected from R120G, Q131G, H146A, Q148G, and K209A.

4. The composition of claim 5, wherein the mutation is Q148G.

5. The composition of any one of the above claims, wherein the CCL20 is wild type.

6. The composition of any one of the above claims for use as a medicament.

7. The use of the composition of any one of the above claims in the manufacture of a medicament for the treatment of cancer.

8. The use of the composition of any one of the above claims in the manufacture of a medicament for modulating of immune response.

CLAIMS

1. A fusion protein comprising at least two cytokines, of which at least one cytokine is modified in such a way that it has a strongly reduced binding activity to its receptor.
2. The fusion protein according to claim 1, further comprising a GGS linker.
3. The fusion protein according to claim 1 or 2, wherein said cytokines are XCL1 and IFNα2.
4. The fusion protein according to claim 1 or 2, wherein said cytokines are CCL20 and ILβ.
5. The fusion protein according to claim 1 or 2, wherein said cytokines are TNF and leptin.
6. A fusion protein according to any of the preceding claims for use as a medicament.
7. A fusion protein according to any of the claims 1-5 for use in treatment of cancer.
8. A fusion protein according to any of the claims 1-5 for use in modulation of the immune response.